- Interview with Dr. Neha Vapiwala Reflecting on ASTRO Presidency and Radiation Oncology
- Meet our 2026-2027 RTOG Foundation Communications Interns
- New Investigator Spotlight: Dr. Christina Henson
- RTOG 3523 Upcoming Events
- ASTRO 2026 Recap
- Webinars
- Save the Date for the 2027 RTOG Investigators Meeting
| | |
Leadership, Advocacy, and the Future of Radiation Oncology: A Coversation with Outgoing ASTRO President, Neha Vapiwala, MD, FASTRO
| | The 2026-2027 RTOG Foundation Communications Interns, Dr. Tugce Kutuk and Dr. Sarthak Shah, interviewed Neha Vapiwala, MD, FASTRO, President of the American Society for Radiation Oncology, about her path into radiation oncology, her leadership journey, and her priorities as ASTRO president. Dr. Vapiwala also discusses the role of the RTOG Foundation and NRG Oncology in advancing clinical research and opportunities for collaboration across the specialty. | | | Meet the 2026-2027 RTOG Foundation Communications Interns | | RTOG Foundation (RTOGF) recently selected two communications interns to help RTOGF create social media content around RTOGF clinical trials. The internship is a 12-month position starting July 1, 2026 and will allow each intern a way to get more involved with the RTOGF organization and cancer research. Interns will be also attending virtual meetings with the RTOGF Communications Committee, attending RTOGF Board Meetings, and have the opportunity to attend an RTOGF Investigators Meeting as well as one of the NRG Oncology Meetings. | | | New Investigator Spotlight: Dr. Christina Henson | | Dr. Christina Henson is a radiation oncologist and clinical researcher at the University of Oklahoma Health Sciences Center, where she currently serves as Assistant Dean for Graduate Medical Education and Executive Vice Chair of Radiation Oncology. Her career focuses on advancing evidence-based, patient-centered cancer care, with particular expertise in head and neck cancers, breast cancer, radiation therapy, immunotherapy, and treatment de-escalation. She has served as principal and site investigator on national and investigator-initiated clinical trials, including studies of novel radiation approaches, immunotherapy, proton therapy, and quality-of-life outcomes. | | | |
RTOG 3523 Upcoming Events | |
REGISTER TODAY: RTOG 3523 MOMENTUM-1 Study Webinar
If you missed our last RTOG 3523 “MOMENTUM-1” study webinar, we will be hosting another one for this series on October 27, 2026. MOMENTUM-1 is a multicenter, randomized, open-label, phase II study of [177Lu] Lu-Dotatate in adults with progressive intracranial grade 1-3 meningioma. During this webinar you will hear updates regarding the MOMENTUM-1 study and there will be a special focus on dosimetry. Sites will be able to ask our study team questions regarding the study at the end of the presentation. Register here
| |
RTOG 3523 Investigators Meeting at SNO 2027
If you are attending the 2027 Society for Neuro-Oncology Annual Meeting in Philadelphia, stop by the Independence Room at the Philadelphia Marriott Downtown for a special RTOG 3523 “MOMENTUM-1” Investigators Meeting. Enjoy refreshments and discuss the study with our study team and other site investigators. Registration is required. Register here
| |
RTOG 3523 at NRG 2027
This year at the 2027 NRG Oncology Winter Meeting, during the RTOG Foundation Investigators Meeting, the RTOG 3523 “MOMENTUM-1” study team will be presenting on the MOMENTUM-1 study including overviews, updates, and more. Join us on Thursday evening January 28, 2027. Registration will open soon!
|
| |
RTOG Foundation and NRG Oncology research was presented during several sessions at the 68th American Society for Radiation Oncology (ASTRO) Annual Meeting. This included the results of the RTOG 3506 “STEEL” trial noting the addition of enzalutamide to standard androgen deprivation therapy (sADT) improved progression free survival compared to sADT alone in high-risk recurrent prostate cancer. These results were presented as an oral presentation during the “Intensify, Shorten, or Personalize? Modern Approaches to Post-prostatectomy RT” session. Click here for more information.
Check this special broadcast from NRG Oncology highlighting press releases and NRG Oncology Podcast episodes on research results presented in the Plenary, Clinical Trials, and Late Breaking Abstract sessions: conta.cc/4d23LAn.
| | REGISTER TODAY: Therapeutic Radiopharmaceuticals - Where Specialties Combine to Bring Novel Cancer Interventions | Join us for the next Radiation Oncology Webinar Series on October 21, 2026 from 4:00-6:00 PM ET. This session is titled "Therapeutic Radiopharmaceuticals - Where Specialties Combine to Bring Novel Cancer Interventions" and will feature presentations on clinical RPT dosimetry, PSMA theranostics, and imaging in theranostics. There will be an opportunity for attendees to ask our speakers questions regarding the topics discussed. This activity has been approved for AMA PRA Category 1 Credit™. | | 2027 RTOG Foundation Investigators Meeting | | Save the date for our next annual RTOG Foundation Investigators Meeting at the 2027 NRG Oncology Winter Meeting in Las Vegas, Nevada on Thursday evening January 28, 2026. Meeting registration will be opening soon! | |
Did You Know?
There are several ways you can participate in RTOG Foundation as a member site, an industry collaborator, or by enrolling in one of our studies. Read more on our website about how you can partner with RTOG Foundation.
Learn more at www.RTOG.org/Partners
| | | | |
